Skip to main content

Advertisement

Table 1 Breast cancer and prostate cancer repositioned drug candidates identified from analysis of LINCS. Complete lists of repositioned drug candidates for breast cancer and prostate cancer are shown in Additional file 13

From: A network based approach to drug repositioning identifies plausible candidates for breast cancer and prostate cancer

  Breast Cancer   Prostate Cancer  
Total compounds 3678   4228  
Compounds that are FDA drugs 632   676  
Compounds that are FDA drugs for target disease 20   11  
Compounds that are in clinical trial for target disease 154   106  
  UCDB DCUB UCDB DCUB
Compounds with FDR < 0.05 2435 1875 2500 1668
Compounds that are clinical drugs with FDR < 0.05 (p-value) 131 (6.2E-8) 109 (2.7E-7) 82 (4.9E-5) 67 (4.8E-7)
FDA drugs with FDR < 0.05 427 325 456 317
FDA drugs with FDR < 0.05 in both UCDB and DCUB 244   291  
FDA drugs for target disease with FDR < 0.05 (p-value) 20 (2.5E-4) 19 (2.7E-5) 10 (2.6E-2) 9 (5.3E-3)
AUC (p-value) 0.86 (<1.0E-6) 0.81 (<1.0E-6) 0.77 (9E-3) 0.83 (4.7E-5)
Number of MAG/DRG 237/700 75/100 333/100 46/100